vorapaxar impurity A - Names and Identifiers
vorapaxar impurity A - Physico-chemical Properties
Molecular Formula | C29H35FN2O8S
|
Molar Mass | 590.66 |
Storage Condition | -20℃ |
Use | Uses Volapasha sulfate is a new antiplatelet drug being developed by Schering Pya for the treatment and prevention of atherosclerotic thrombosis. Currently, it is conducting phase III clinical trials for secondary prevention of cardiovascular events in patients with acute coronary syndrome (unstable angina/non-ST-segment elevation myocardial infarction) and high-risk patients. |
vorapaxar impurity A - Preparation solution concentration reference
| 1mg | 5mg | 10mg |
---|
1 mM | 1.693 ml | 8.465 ml | 16.93 ml |
5 mM | 0.339 ml | 1.693 ml | 3.386 ml |
10 mM | 0.169 ml | 0.847 ml | 1.693 ml |
5 mM | 0.034 ml | 0.169 ml | 0.339 ml |
Last Update:2024-01-02 23:10:35
vorapaxar impurity A - Reference Information
use | Volapasha sulfate is a new antiplatelet drug being developed by Schering Pya for the treatment and prevention of atherosclerotic thrombosis. Currently, it is conducting phase III clinical trials for secondary prevention of cardiovascular events in patients with acute coronary syndrome (unstable angina/non-ST-segment elevation myocardial infarction) and high-risk patients. |
Pharmacological action | Volapasa sulfate (vorapaxar sulfate) is a brand new protease-activated receptor 1( PAR-1) Antagonists are effective and highly selective orally, and can inhibit platelet aggregation induced by thrombin. In May 2014, the U.S. Food and Drug Administration (FDA) approved it for patients with a history of myocardial infarction or peripheral arterial disease to reduce thrombotic cardiovascular events. |
Last Update:2024-04-10 22:29:15